Eisai Global
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Japan · 10K+ Employees
View Company Info for Free
Overview
Headquarters
4-6-10 Koishikawa Bunkyo-ku, Tokyo, Toky...Phone Number
+81 338173700Website
eisai.comRevenue
$5.1 BillionStock Symbol
ESAIYIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
9
8
1
2
1
1
About Eisai Global
Eisai is a global pharmaceutical manufacturing company founded in 1941. The company develops and produces medicines while focusing on a human health care approach that extends beyond traditional pharmaceutical services. Eisai operates across multiple regions including North America, Europe, Asia Pacific, and the Middle East, with a strong presence in countries such as the United States, Japan, China, and the United Kingdom. The company maintains a significant focus on research and development in the pharmaceutical sector, with particular emphasis on patient-centered healthcare solutions. Eisai's business model encompasses both business-to-business and business-to-consumer operations, reflecting its comprehensive approach to healthcare delivery and pharmaceutical development.Explore more
Eisai Global Org Chart
BW
Vice President
SY
Vice President
JK
Vice President, Clinical Development
JZ
Vice President and Head of MBE Division
KA
Vice President
SS
Vice President, China Business Japan, Asia Fi...
MK
Strategy Vice President, Supply Chain
LO
Vice President, Quality Operations
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eisai Global your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Eisai Global had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Eisai Global has new funding data
Product Launch: Get notified when Eisai Global launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Eisai Global recently announced quarterly report
Check if Eisai Global has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Eisai Global
Eisai Global, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Eisai Global is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Eisai Global
Compare insights from companies similar to Eisai Global, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Eisai Global
$5.1B
10K+
Public
-
1941
Tatsuyuki YasunoChairman & CEO & Eisai Inc Region President (Americas)
$5.9B
10K+
Public
-
1928
MD
Michael DavisSenior Vice President, Chief Marketing Officer, Head of Stakeholder Integration
Company Profile Activity
Activity Insights
Eisai Global is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Eisai Global is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Eisai Global.
Eisai Global Tech Stack
A closer look at the technologies used by Eisai Global
See more technologies
Most Recent Scoops
Open Position
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals
Open Position
Hiring Plans
Hiring Plans
Eisai Global News & Media
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., May 8, 2026 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a...Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once-weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIK™) as a starting dose for the treatment of early Alzheimer’s disease. The new Prescription Drug User Fee Act (PDUFA) action dateMerck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
TOKYO and RAHWAY, N.J., Apr 21, 2026 - (JCN Newswire) - Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada), and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced results from the Phase 3 LITESPARK-012 trial evaluating combination treatments for the firstline treatment of patients with advanced clear cell renal cell carcinoma (RCC). The trial evaluated the triplet therapy of KEYTRUDA® (pembrolizumab), Merck & Co., Inc., Rahway,New Survey Data Exploring Patient Experiences with Endometrial Cancer Care Presented at 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer
70% of patients surveyed reported the burden of chemotherapy treatment was almost as great as the burden of the disease itself, and 71% would prefer not to receive it again Findings indicate that patients desire more discussion about treatment options with their physicians, underscoring...
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Eisai Global
Sign Up For FreeTo access detailed company insights
Eisai is a global pharmaceutical manufacturing company founded in 1941. The company develops and produces medicines while focusing on a human health care approach that extends beyond traditional pharmaceutical services. Eisai operates across multiple regions including North America, Europe, Asia Pacific, and the Middle East, with a strong presence... Read More
